A Northwestern-trained physician who teaches, builds trials, and sits on a college board - all in service of one stubborn idea: people with advanced cancer are out of time, and that is a problem worth a whole career.
For years, claudin 18.2 was a footnote - a protein on the surface of stomach cells that looked interesting in slides and went quiet in trials. Then SPOTLIGHT read out. Zolbetuximab plus chemotherapy beat placebo on the measures that matter, progression-free and overall survival, in patients whose tumors carried the marker. Ahsan Arozullah, then leading oncology development at Astellas, put it plainly: this was the first Phase III pivotal trial to validate claudin 18.2 as a target for gastric cancer. A footnote became a franchise.
Today he is Executive Vice President of Research and Development and Chief Medical Officer at TerSera Therapeutics, a specialty pharmaceutical company headquartered in Deerfield, Illinois. The portfolio runs across oncology, CNS disorders, urology and rare disease - the corners of medicine where the patient count is small, the need is loud, and the science has to be exact. His job is to decide which molecules earn a trial, and to keep the people in those trials at the center of every decision.
What makes him unusual is not the title. It is the route. Most R&D chiefs come up through the lab or the deal table. Arozullah came up through the bedside and the lecture hall, then spent two decades learning how a good idea becomes an approved medicine - and how often it doesn't.
That sentence is the whole map. He says it without flourish, the way doctors state a finding. The grief is not a marketing line; it is the reason the trials get built the way they get built.
Begins his medical career as faculty, holding professorships in Internal Medicine and Health Promotion Research. The teaching habit never fully leaves him.
Crosses from academia into industry - the first step in translating clinical questions into developed therapies.
A long climb through clinical development leadership, ending at the top of oncology development and the SPOTLIGHT readout that reset a field.
Positive Phase 3 data for zolbetuximab in CLDN18.2-positive gastric and GEJ cancers - presented at ASCO GI, with Arozullah front and center.
Steering research and development across a specialty portfolio built around unmet need.
Bachelor of Science in Medicine, Doctor of Medicine, and residency - all under one storied roof.
Internal Medicine fellowship plus a Master of Public Health from the School of Public Health - the population view to balance the clinical one.
Member of the American Society of Clinical Oncology and the European Society for Medical Oncology.
"People living with cancer, particularly those with advanced disease, have urgent unmet needs."- AHSAN AROZULLAH, ON WHY THE WORK CAN'T WAIT
His academic research asked an oddly practical question: can you spot a patient with poor health literacy in about seven seconds? Get that right and cancer screening and treatment get better before a single drug is prescribed.
He sits on the board of Darul Qasim College, an Islamic educational institution. An R&D chief who also helps integrate Islamic scholarship into academic discourse is not a combination you see on most org charts.
He's featured by the Initiative on Islam and Medicine, working at the intersection of clinical medicine and bioethics - the questions that sit underneath every consent form.
"Our goal is to ensure people living with cancer can enjoy a longer and higher quality of life."
"We collaborate with top scientists, clinicians, and caretakers from around the world to develop novel therapies."
"SPOTLIGHT is the first Phase III pivotal trial to validate CLDN18.2 as a target for gastric cancer."
"Cancer challenges all of us directly through the impact on people's lives and their families."
Two of American medicine's most storied names on one CV: Northwestern for the MD, Harvard for the MPH.
Before the boardroom, he was a professor - teaching internal medicine and health promotion research.
His research portfolio spans the frontier of oncology targets and the everyday problem of whether patients can read their own care instructions.
TerSera runs out of Deerfield, Illinois - a quiet Chicago suburb that happens to be a hub for specialty pharma.